Studies have shown that OCCC cells are susceptible to knockdown of epigenetic gene targets such as bromopseudomin and the extraterminal domain (BET) proteins BRD2 and BRD3, and targeting the BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition may as a therapeutic strategy for ovarian clear cell carcinoma (119). Here, BRD3 is linked to ovarian clear cell cancer.